All In Biotech

Drug Trial Radar · NCT00656136

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)

Last checked: Nov 19, 2026Latest source record: Jul 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 585 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

585

Actual

Start

Apr 2008

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed. The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • placeboDrug

    Patients receive placebo once daily

  • BIBW 2992Drug

    Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization until death or the last patient out date, an average of 12 months

Locations

90 sites in 15 countries. Site status is shown where the registry gives one.

  • 1200.23.038 Boehringer Ingelheim Investigational Site

    Kingman, Arizona

  • 1200.23.046 Boehringer Ingelheim Investigational Site

    Fayetteville, Arkansas

  • 1200.23.027 Boehringer Ingelheim Investigational Site

    Anaheim, California

  • 1200.23.028 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 1200.23.029 Boehringer Ingelheim Investigational Site

    Modesto, California

  • 1200.23.045 Boehringer Ingelheim Investigational Site

    Montebello, California

  • 1200.23.009 Boehringer Ingelheim Investigational Site

    Orange, California

  • 1200.23.026 Boehringer Ingelheim Investigational Site

    Palm Springs, California

  • 1200.23.024 Boehringer Ingelheim Investigational Site

    North Miami Beach, Florida

  • 1200.23.020 Boehringer Ingelheim Investigational Site

    New York, New York

  • 1200.23.013 Boehringer Ingelheim Investigational Site

    Valhalla, New York

  • 1200.23.056 Boehringer Ingelheim Investigational Site

    Salt Lake City, Utah

  • 1200.23.039 Boehringer Ingelheim Investigational Site

    Renton, Washington

  • 1200.23.050 Boehringer Ingelheim Investigational Site

    Seattle, Washington

  • 1200.23.32004 Boehringer Ingelheim Investigational Site

    Edegem, Belgium

  • 1200.23.32003 Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • 1200.23.32001 Boehringer Ingelheim Investigational Site

    Leuven, Belgium

  • 1200.23.32005 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1200.23.32006 Boehringer Ingelheim Investigational Site

    Namur, Belgium

  • 1200.23.1002 Boehringer Ingelheim Investigational Site

    Edmonton, Alberta, Canada

  • 1200.23.1005 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1200.23.1009 Boehringer Ingelheim Investigational Site

    Toronto, Ontario, Canada

  • 1200.23.1001 Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

  • 1200.23.1004 Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

  • 1200.23.86001 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1200.23.86002 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1200.23.86003 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 1200.23.86009 Boehringer Ingelheim Investigational Site

    Chengdu, China

  • 1200.23.86007 Boehringer Ingelheim Investigational Site

    Guangzhou, China

  • 1200.23.86008 Boehringer Ingelheim Investigational Site

    Hangzhou, China

  • 1200.23.86004 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 1200.23.86005 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 1200.23.86006 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 1200.23.3303A Boehringer Ingelheim Investigational Site

    Besançon, France

  • 1200.23.3303C Boehringer Ingelheim Investigational Site

    Besançon, France

  • 1200.23.3305A Boehringer Ingelheim Investigational Site

    Caen, France

  • 1200.23.3304A Boehringer Ingelheim Investigational Site

    La Tronche, France

  • 1200.23.3304B Boehringer Ingelheim Investigational Site

    La Tronche, France

  • 1200.23.3307A Boehringer Ingelheim Investigational Site

    Lyon, France

  • 1200.23.3301A Boehringer Ingelheim Investigational Site

    Paris, France

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.